TYK2 in Immune Responses and Treatment of Psoriasis

References

• Armstrong AW, Read C. Read, pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945–1960. doi:10.1001/jama.2020.4006
   PubMed Web of Science ®Google Scholar
• Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–212. doi:10.1111/jdv.13854
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–994. doi:10.1016/S0140-6736(14)61909-7
   PubMed Web of Science ®Google Scholar
• Greb JE, Goldminz AM, Elder JT, et al. Psoriasis. Nat Rev Dis Primers. 2016;2:16082. doi:10.1038/nrdp.2016.82
   PubMed Web of Science ®Google Scholar
• Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645–653. doi:10.1016/j.jaci.2017.07.004
   PubMed Web of Science ®Google Scholar
• Howell MD, Kuo FI, Smith PA. Targeting the Janus Kinase family in autoimmune skin diseases. Front Immunol. 2019;10:2342. doi:10.3389/fimmu.2019.02342
   PubMed Web of Science ®Google Scholar
• Schwartz DM, Bonelli M, Gadina M, et al. Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12(1):25–36. doi:10.1038/nrrheum.2015.167
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Schwartz DM, Villarino AV, et al. The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med. 2015;66:311–328. doi:10.1146/annurev-med-051113-024537
   PubMed Web of Science ®Google Scholar
• Burke JR, Cheng L, Gillooly KM, et al. Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain. Sci Transl Med. 2019;11:502. doi:10.1126/scitranslmed.aaw1736
   Web of Science ®Google Scholar
• Parham C, Chirica M, Timans J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol. 2002;168(11):5699–5708. doi:10.4049/jimmunol.168.11.5699
   PubMed Web of Science ®Google Scholar
• Boutet MA, Nerviani A, Gallo Afflitto G, et al. Role of the IL-23/IL-17 axis in psoriasis and psoriatic arthritis: the clinical importance of its divergence in skin and joints. Int J Mol Sci. 2018;19:2. doi:10.3390/ijms19020530
   Web of Science ®Google Scholar
• Ghoreschi K, Balato A, Enerbäck C, et al. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021;397(10275):754–766. doi:10.1016/S0140-6736(21)00184-7
   PubMed Web of Science ®Google Scholar
• Villarino AV, Kanno Y, O’Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol. 2017;18(4):374–384. doi:10.1038/ni.3691
   PubMed Web of Science ®Google Scholar
• Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol. 2017;13(4):234–243. doi:10.1038/nrrheum.2017.23
   PubMed Web of Science ®Google Scholar
• Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843–862. doi:10.1038/nrd.2017.201
   PubMed Web of Science ®Google Scholar
• McNally R, Eck MJ. JAK-cytokine receptor recognition, unboxed. Nat Struct Mol Biol. 2014;21(5):431–433. doi:10.1038/nsmb.2824
   PubMed Web of Science ®Google Scholar
• Jatiani SS, Baker SJ, Silverman LR, et al. Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. Genes Cancer. 2010;1(10):979–993. doi:10.1177/1947601910397187
   PubMedGoogle Scholar
• Tokuyama M, Mabuchi T. New treatment addressing the pathogenesis of psoriasis. Int J Mol Sci. 2020;21:20. doi:10.3390/ijms21207488
   Web of Science ®Google Scholar
• Hawkes JE, Yan BY, Chan TC, et al. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018;201(6):1605–1613. doi:10.4049/jimmunol.1800013
   PubMed Web of Science ®Google Scholar
• Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496–509. doi:10.1056/NEJMra0804595
   PubMed Web of Science ®Google Scholar
• He X, Chen X, Zhang H, et al. Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015–2018). Expert Opin Ther Pat. 2019;29(2):137–149. doi:10.1080/13543776.2019.1567713
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228(1):273–287. doi:10.1111/j.1600-065X.2008.00754.x
   PubMed Web of Science ®Google Scholar
• Liang Y, Zhu Y, Xia Y, et al. Therapeutic potential of tyrosine kinase 2 in autoimmunity. Expert Opin Ther Targets. 2014;18(5):571–580. doi:10.1517/14728222.2014.892925
   PubMed Web of Science ®Google Scholar
• Nogueira M, Puig L, Torres T. JAK inhibitors for treatment of psoriasis: focus on selective TYK2 Inhibitors. Drugs. 2020;80(4):341–352. doi:10.1007/s40265-020-01261-8
   PubMed Web of Science ®Google Scholar
• Schön MP, Erpenbeck L. The interleukin-23/interleukin-17 axis links adaptive and innate immunity in psoriasis. Front Immunol. 2018;9:1323. doi:10.3389/fimmu.2018.01323
   PubMed Web of Science ®Google Scholar
• Tobin AM, Lynch L, Kirby B, et al. Natural killer cells in psoriasis. J Innate Immun. 2011;3(4):403–410. doi:10.1159/000328011
   PubMed Web of Science ®Google Scholar
• Gaspari AA. Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol. 2006;54(3 Suppl):S67–80. doi:10.1016/j.jaad.2005.10.057
   PubMed Web of Science ®Google Scholar
• Aizu K, Li W, Yajima T, et al. An important role of Tyk2 in APC function of dendritic cells for priming CD8+ T cells producing IFN-gamma. Eur J Immunol. 2006;36(11):3060–3070. doi:10.1002/eji.200636173
   PubMed Web of Science ®Google Scholar
• Ho LJ, Hung L-F, Weng C-Y, et al. Dengue virus type 2 antagonizes IFN-alpha but not IFN-gamma antiviral effect via down-regulating Tyk2-STAT signaling in the human dendritic cell. J Immunol. 2005;174(12):8163–8172. doi:10.4049/jimmunol.174.12.8163
   PubMed Web of Science ®Google Scholar
• Conzelmann M, Wagner AH, Hildebrandt A, et al. IFN-γ activated JAK1 shifts CD40-induced cytokine profiles in human antigen-presenting cells toward high IL-12p70 and low IL-10 production. Biochem Pharmacol. 2010;80(12):2074–2086. doi:10.1016/j.bcp.2010.07.040
   PubMed Web of Science ®Google Scholar
• Tokumasa N, Suto A, Kagami S-I, et al. Expression of Tyk2 in dendritic cells is required for IL-12, IL-23, and IFN-gamma production and the induction of Th1 cell differentiation. Blood. 2007;110(2):553–560. doi:10.1182/blood-2006-11-059246
   PubMed Web of Science ®Google Scholar
• Simonović N, Witalisz-Siepracka A, Meissl K, et al. NK cells require cell-extrinsic and -intrinsic TYK2 for full functionality in tumor surveillance and antibacterial immunity. J Immunol. 2019;202(6):1724–1734. doi:10.4049/jimmunol.1701649
   PubMed Web of Science ®Google Scholar
• Shimoda K, Tsutsui H, Aoki K, et al. Partial impairment of interleukin-12 (IL-12) and IL-18 signaling in Tyk2-deficient mice. Blood. 2002;99(6):2094–2099. doi:10.1182/blood.V99.6.2094
   PubMed Web of Science ®Google Scholar
• Fuchs S, Kaiser-Labusch P, Bank J, et al. Tyrosine kinase 2 is not limiting human antiviral type III interferon responses. Eur J Immunol. 2016;46(11):2639–2649. doi:10.1002/eji.201646519
   PubMed Web of Science ®Google Scholar
• Strobl B, Bubic I, Bruns U, et al. Novel functions of tyrosine kinase 2 in the antiviral defense against murine cytomegalovirus. J Immunol. 2005;175(6):4000–4008. doi:10.4049/jimmunol.175.6.4000
   PubMed Web of Science ®Google Scholar
• Novak U, Harpur AG, Paradiso L, et al. Colony-stimulating factor 1-induced STAT1 and STAT3 activation is accompanied by phosphorylation of Tyk2 in macrophages and Tyk2 and JAK1 in fibroblasts. Blood. 1995;86(8):2948–2956. doi:10.1182/blood.V86.8.2948.2948
   PubMed Web of Science ®Google Scholar
• Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. 2014;32:513–545. doi:10.1146/annurev-immunol-032713-120231
   PubMed Web of Science ®Google Scholar
• Rönnblom L. The importance of the type I interferon system in autoimmunity. Clin Exp Rheumatol. 2016;34(4 Suppl):21–24.
   PubMed Web of Science ®Google Scholar
• Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014;14(1):36–49. doi:10.1038/nri3581
   PubMed Web of Science ®Google Scholar
• Li F, Zhang R, Hu C, et al. Irradiation haematopoiesis recovery orchestrated by IL-12/IL-12Rβ1/TYK2/STAT3-initiated osteogenic differentiation of mouse bone marrow-derived mesenchymal stem cells. Front Cell Dev Biol. 2021;9:729293. doi:10.3389/fcell.2021.729293
   PubMed Web of Science ®Google Scholar
• Watford WT, Hissong BD, Bream JH, et al. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev. 2004;202:139–156. doi:10.1111/j.0105-2896.2004.00211.x
   PubMed Web of Science ®Google Scholar
• Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13(5):715–725. doi:10.1016/S1074-7613(00)00070-4
   PubMed Web of Science ®Google Scholar
• Sohn SJ, Barrett K, Van Abbema A, et al. A restricted role for TYK2 catalytic activity in human cytokine responses revealed by novel TYK2-selective inhibitors. J Immunol. 2013;191(5):2205–2216. doi:10.4049/jimmunol.1202859
   PubMed Web of Science ®Google Scholar
• Karaghiosoff M, Neubauer H, Lassnig C, et al. Partial impairment of cytokine responses in Tyk2-deficient mice. Immunity. 2000;13(4):549–560. doi:10.1016/S1074-7613(00)00054-6
   PubMed Web of Science ®Google Scholar
• Shaw MH, Boyartchuk V, Wong S, et al. A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity. Proc Natl Acad Sci U S A. 2003;100(20):11594–11599. doi:10.1073/pnas.1930781100
   PubMed Web of Science ®Google Scholar
• Ishizaki M, Muromoto R, Akimoto T, et al. Tyk2 is a therapeutic target for psoriasis-like skin inflammation. Int Immunol. 2014;26(5):257–267. doi:10.1093/intimm/dxt062
   PubMed Web of Science ®Google Scholar
• Trivella DB, Ferreira-Júnior JR, Dumoutier L, et al. Structure and function of interleukin-22 and other members of the interleukin-10 family. Cell Mol Life Sci. 2010;67(17):2909–2935. doi:10.1007/s00018-010-0380-0
   PubMed Web of Science ®Google Scholar
• Wolk K, Witte E, Witte K, et al. Biology of interleukin-22. Semin Immunopathol. 2010;32(1):17–31. doi:10.1007/s00281-009-0188-x
   PubMed Web of Science ®Google Scholar
• Van Belle AB, de Heusch M, Lemaire MM, et al. IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice. J Immunol. 2012;188(1):462–469. doi:10.4049/jimmunol.1102224
   PubMed Web of Science ®Google Scholar
• Wolk K, Haugen HS, Xu W, et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. J Mol Med (Berl). 2009;87(5):523–536. doi:10.1007/s00109-009-0457-0
   PubMed Web of Science ®Google Scholar
• Ma HL, Liang S, Li J, et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest. 2008;118(2):597–607. doi:10.1172/JCI33263
   PubMed Web of Science ®Google Scholar
• Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15(4):234–248. doi:10.1038/nrclinonc.2018.8
   PubMed Web of Science ®Google Scholar
• Garbers C, Aparicio-Siegmund S, Rose-John S. The IL-6/gp130/STAT3 signaling axis: recent advances towards specific inhibition. Curr Opin Immunol. 2015;34:75–82. doi:10.1016/j.coi.2015.02.008
   PubMed Web of Science ®Google Scholar
• Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. Nat Immunol. 2015;16(5):448–457. doi:10.1038/ni.3153
   PubMed Web of Science ®Google Scholar
• Ishizaki M, Muromoto R, Akimoto T, et al. Tyk2 deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Int Immunol. 2011;23(9):575–582. doi:10.1093/intimm/dxr057
   PubMed Web of Science ®Google Scholar
• Berekmeri A, Mahmood F, Wittmann M, et al. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2018;14(9):719–730. doi:10.1080/1744666X.2018.1512404
   PubMed Web of Science ®Google Scholar
• Traynor K. FDA approves tofacitinib for rheumatoid arthritis. Am J Health Syst Pharm. 2012;69(24):2120.
   Web of Science ®Google Scholar
• Papp KA, Menter MA, Raman M, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2016;174(6):1266–1276. doi:10.1111/bjd.14403
   PubMed Web of Science ®Google Scholar
• Hosking AM, Juhasz M, Mesinkovska NA. Topical Janus kinase inhibitors: a review of applications in dermatology. J Am Acad Dermatol. 2018;79(3):535–544. doi:10.1016/j.jaad.2018.04.018
   PubMed Web of Science ®Google Scholar
• Xie F, Yun H, Bernatsky S, et al. Brief report: risk of gastrointestinal perforation among rheumatoid arthritis patients receiving tofacitinib, tocilizumab, or other biologic treatments. Arthritis Rheumatol. 2016;68(11):2612–2617. doi:10.1002/art.39761
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Lebwohl M, Cohen AD, et al. Herpes zoster in psoriasis patients treated with tofacitinib. J Am Acad Dermatol. 2017;77(2):302–309. doi:10.1016/j.jaad.2017.03.023
   PubMed Web of Science ®Google Scholar
• Olivera PA, Lasa JS, Bonovas S, et al. Safety of Janus Kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology. 2020;158(6):1554–1573.e12. doi:10.1053/j.gastro.2020.01.001
   PubMed Web of Science ®Google Scholar
• Pérez-Jeldres T, Tyler CJ, Boyer JD, et al. Targeting cytokine signaling and lymphocyte traffic via small molecules in inflammatory bowel disease: JAK inhibitors and S1PR agonists. Front Pharmacol. 2019;10:212. doi:10.3389/fphar.2019.00212
   PubMed Web of Science ®Google Scholar
• Danese S, Argollo M, Le Berre C, et al. JAK selectivity for inflammatory bowel disease treatment: does it clinically matter? Gut. 2019;68(10):1893–1899. doi:10.1136/gutjnl-2019-318448
   PubMed Web of Science ®Google Scholar
• Gadina M, Chisolm DA, Philips RL, et al. Translating JAKs to Jakinibs. J Immunol. 2020;204(8):2011–2020. doi:10.4049/jimmunol.1901477
   PubMed Web of Science ®Google Scholar
• Dendrou CA, Cortes A, Shipman L, et al. Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity. Sci Transl Med. 2016;8(363):363ra149. doi:10.1126/scitranslmed.aag1974
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Jesson MI, Li X, et al. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). J Immunol. 2011;186(7):4234–4243. doi:10.4049/jimmunol.1003668
   PubMed Web of Science ®Google Scholar
• Bellinato F, Gisondi P, Girolomoni G. Latest advances for the treatment of chronic plaque psoriasis with biologics and oral small molecules. Biologics. 2021;15:247–253.
   PubMed Web of Science ®Google Scholar
• Chimalakonda A, Burke J, Cheng L, et al. Selectivity profile of the tyrosine kinase 2 inhibitor deucravacitinib compared with Janus Kinase 1/2/3 Inhibitors. Dermatol Ther. 2021;11(5):1763–1776. doi:10.1007/s13555-021-00596-8
   PubMed Web of Science ®Google Scholar
• Papp K, Gordon K, Thaçi D, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med. 2018;379(14):1313–1321. doi:10.1056/NEJMoa1806382
   PubMed Web of Science ®Google Scholar
• Catlett IM, Hu Y, Gao L, et al. Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis. J Allergy Clin Immunol. 2021;149:2010–2020.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2022. doi:10.1016/j.jaad.2022.07.002
   Google Scholar
• Page KM, Suarez-Farinas M, Suprun M, et al. Molecular and cellular responses to the TYK2/JAK1 Inhibitor PF-06700841 reveal reduction of skin inflammation in plaque psoriasis. J Invest Dermatol. 2020;140(8):1546–1555.e4. doi:10.1016/j.jid.2019.11.027
   PubMed Web of Science ®Google Scholar
• Banfield C, Scaramozza M, Zhang W, et al. The safety, tolerability, pharmacokinetics, and pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in healthy subjects and patients with plaque psoriasis. J Clin Pharmacol. 2018;58(4):434–447. doi:10.1002/jcph.1046
   PubMed Web of Science ®Google Scholar
• Forman SB, Pariser DM, Poulin Y, et al. TYK2/JAK1 Inhibitor PF-06700841 in patients with plaque psoriasis: phase IIa, randomized, double-blind, placebo-controlled trial. J Invest Dermatol. 2020;140(12):2359–2370.e5. doi:10.1016/j.jid.2020.03.962
   PubMed Web of Science ®Google Scholar
• Gerstenberger BS, Ambler C, Arnold EP, et al. Discovery of tyrosine kinase 2 (TYK2) Inhibitor (PF-06826647) for the treatment of autoimmune diseases. J Med Chem. 2020;63(22):13561–13577. doi:10.1021/acs.jmedchem.0c00948
   PubMed Web of Science ®Google Scholar
• Singh R, Pradhan V, Roberts ES, et al. Safety and pharmacokinetics of the oral TYK2 inhibitor PF-06826647: a Phase I, randomized, double-blind, placebo-controlled, Dose-Escalation Study. Clin Transl Sci. 2021;14(2):671–682. doi:10.1111/cts.12929
   PubMed Web of Science ®Google Scholar
• Tehlirian C, Singh RSP, Pradhan V, et al. Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2022;87(2):333–342. doi:10.1016/j.jaad.2022.03.059
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Bourcier M, Gooderham M, et al. Management of moderate to severe plaque psoriasis: the emerging role of IL-17 inhibition. J Cutan Med Surg. 2017;21(2_suppl):2S–40S. doi:10.1177/1203475417722552
   PubMed Web of Science ®Google Scholar
• Menter A, Thaçi D, Wu JJ, et al. Long-term safety and effectiveness of adalimumab for moderate to severe psoriasis: results from 7-year interim analysis of the ESPRIT registry. Dermatol Ther (Heidelb). 2017;7(3):365–381. doi:10.1007/s13555-017-0198-x
   PubMed Web of Science ®Google Scholar
• Kalb RE, Fiorentino DF, Lebwohl MG, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol. 2015;151(9):961–969. doi:10.1001/jamadermatol.2015.0718
   PubMed Web of Science ®Google Scholar
• Van Voorhees AS, Stein Gold L, Lebwohl M, et al. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study. J Am Acad Dermatol. 2020;83(1):96–103. doi:10.1016/j.jaad.2020.01.072
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Xeljanz: product information; 2017. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/.xeljanz. Accessed August 3, 2022.
   Google Scholar
• Food and Drug Administration. Xeljanz: FDA approves new treatment for moderately to severely active ulcerative colitis; 2018. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-moderately-severely-active-ulcerative-colitis. Accessed August 3, 2022.
   Google Scholar
• FitzGerald O, Gladman D, Mease P, et al. Biomarker changes with selective tyrosine kinase 2 inhibitor, deucravacitinib, in PsA: effects on disease markers and tyrosine kinase 2‒ versus Janus Kinase 1/2/3‒mediated Pathways [abstract]. Arthritis Rheumatol. 2021;73(suppl 10):1305–1458
   Google Scholar
• Tehlirian C, Peeva E, Kieras E, et al. Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of the oral TYK2 inhibitor PF-06826647 in participants with plaque psoriasis: a phase 1, randomised, double-blind, placebo-controlled, parallel-group study. Lancet Rheumatol. 2021;3(3):e204–e213. doi:10.1016/S2665-9913(20)30397-0
   PubMedGoogle Scholar
• Gordon K, Gooderham M, Papp K, et al. BMS- 986165, an oral, selective tyrosine kinase 2 (TYK2) inhibitor: evaluation of changes in laboratory parameters in response to treatment in a Phase 2 trial in psoriasis [poster]. Presented at: the American Academy of Dermatology Annual Meeting. Denver, CO; 2020.
   Google Scholar